0000000000021900

AUTHOR

Joakim Dillner

showing 9 related works from this author

Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer

1997

Background: Major risk factors for invasive cervical cancer include infection with human papillomavirus (HPV), infection with other sexually transmitted pathogens (e.g., Chlamydia trachomatis), and smoking. Since exposures to these risk factors can be related, the contribution of any single factor to cervical carcinogenesis has been difficult to assess. We conducted a prospective study to define the role of HPV infection in cervical carcinogenesis, with invasive cancer as an end point. Methods: A nested case‐control study within a joint cohort of 700 000 Nordic subjects was performed. The 182 women who developed invasive cervical cancer during a mean follow-up of 5 years were matched with 5…

AdultRiskCancer Researchmedicine.medical_specialtyRadioimmunoassaySexually Transmitted DiseasesUterine Cervical NeoplasmsAdenocarcinomamedicine.disease_causeSerology03 medical and health sciences0302 clinical medicineRisk FactorsSeroepidemiologic StudiesInternal medicinePrevalencemedicineHumansNeoplasm InvasivenessProspective Studies030212 general & internal medicinePapillomaviridaeRisk factorPapillomaviridaeGynecologyCervical cancerbiologybusiness.industryIncidencePapillomavirus InfectionsHPV infectionCancerMiddle Agedbiology.organism_classificationmedicine.disease3. Good healthTumor Virus InfectionsOncologyCase-Control Studies030220 oncology & carcinogenesisRelative riskCarcinoma Squamous CellFemalebusinessChlamydia trachomatis
researchProduct

A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in c…

1996

To estimate the risk of developing cervical intra-epithelial neoplasia (CIN) among women exposed to human papillomavirus (HPV) type 16, we performed a prospective study in a population-based cohort of more than 15,000 women followed for 34.9 months. Seventy-four women developed CIN during follow-up and were matched for age, time of sampling and area of residence with 148 women who remained CIN-free during follow-up. The blood samples taken at enrollment were tested for serum antibodies to HPV types 16, 18 and 33 capsids. Cervical smears or biopsies were analyzed for the presence of HPV DNA by nested PCR using HPV general primers and by HPV 16- and 18-type-specific PCR. HPV serology and HPV-…

AdultCancer Researchmedicine.medical_specialtyPopulationCervix UteriAntibodies ViralPolymerase Chain ReactionSerologyCohort StudiesRisk FactorsInternal medicineCarcinomamedicineHumansProspective StudiesRisk factorProspective cohort studyeducationPapillomaviridaeSwedenVaginal SmearsGynecologyeducation.field_of_studybusiness.industryPapillomavirus InfectionsAge FactorsAbsolute risk reductionvirus diseasesMiddle AgedUterine Cervical Dysplasiamedicine.diseasefemale genital diseases and pregnancy complicationsTumor Virus InfectionsOncologyDNA ViralCohortFemalebusinessPapanicolaou TestCohort studyInternational Journal of Cancer
researchProduct

Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis

1999

Human papillomavirus (HPV) exists as more than 100 genotypes. It is not well-established whether the different HPV types interfere with infection or pathogenesis by each other. Possible interactions in cervical carcinogenesis between infection with the most common HPV types (6, 11, 16, 18 and 33) were studied in a seroepidemiological case- control study of 218 women with primary untreated cervical cancer and 219 healthy age-matched control women. As previously shown, HPV-16 seropositivity was associated with cervical cancer risk [odds ratio (OR), 2·39], but HPV-16 was not associated with cervical cancer risk among HPV-6 seropositive women (OR, 1·0). The relative excess risk due to interacti…

Cervical cancerHpv typesPapillomavirus InfectionsAbsolute risk reductionUterine Cervical Neoplasmsvirus diseasesOdds ratioBiologyAntibodies Viralmedicine.diseaseVirologyfemale genital diseases and pregnancy complicationsConfidence intervalPathogenesisTumor Virus InfectionsCervical carcinogenesisSeroepidemiologic StudiesCase-Control StudiesVirologyGenotypemedicineHumansFemalePapillomaviridaeJournal of General Virology
researchProduct

Sero-epidemiologal association between human-papillomavirus infection and risk of prostate cancer

1998

Some epidemiological studies of prostate cancer have suggested the existence of a sexually transmitted risk factor, and some studies have reported the presence of human papillomavirus (HPV) DNA in prostate-cancer tissue. To perform a sero-epidemiological evaluation of whether HPV infection is associated with increased risk for prostate cancer, we performed a nested case-control study within a serum bank containing samples from 20,243 healthy Finnish men. We identified 165 cases of prostate cancer that were diagnosed up to 24 years after donation of the serum sample. Two control subjects per case were selected, matched for gender, age and municipality of residence. Serum samples were analyze…

OncologyCancer Researchmedicine.medical_specialtyChlamydiabusiness.industryCase-control studyHPV infectionmedicine.diseaseSerologyProstate cancermedicine.anatomical_structureOncologyProstateRelative riskInternal medicineImmunologymedicineRisk factorbusinessInternational Journal of Cancer
researchProduct

Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology.

2004

The interaction between human papillomavirus (HPV) particles and cell surface heparan sulfate requires intact conformation of the HPV particles. Type-specific HPV serology is currently based on virus-like particles (VLPs) with intact conformation. Presence of incorrectly folded VLPs in VLP preparations is recognized as an important cause of cross-reactivity in HPV serology. Heparin-coated microtitre plates were evaluated for capturing conformationally correct VLPs and improving the type specificity of HPV serology. Hybrid VLPs between HPV16 and HPV11, which had been found to have significant reactivity with children's sera and a batch of HPV18 VLPs that had failed the quality control becaus…

AdultMaleQuality ControlAdolescentmedicine.drug_classvirusesEnzyme-Linked Immunosorbent AssayBiologyCross ReactionsMonoclonal antibodyAntibodies Viralcomplex mixturesSensitivity and SpecificityEpitopeSerologyMicrobiology in the medical areachemistry.chemical_compoundAntigenVirus-like particleVirologymedicineHumansSerologic TestsChildAntigens ViralPapillomaviridaeAgedAged 80 and overHeparinPapillomavirus Infectionsvirus diseasesHeparan sulfateHeparinMiddle AgedVirologyMolecular biologychemistryChild Preschoolbiology.proteinFemaleAntibodymedicine.drugThe Journal of general virology
researchProduct

European code against cancer 4th edition: 12 ways to reduce your cancer risk

2015

AbstractThis overview describes the principles of the 4th edition of the European Code against Cancer and provides an introduction to the 12 recommendations to reduce cancer risk. Among the 504.6 million inhabitants of the member states of the European Union (EU28), there are annually 2.64 million new cancer cases and 1.28 million deaths from cancer. It is estimated that this cancer burden could be reduced by up to one half if scientific knowledge on causes of cancer could be translated into successful prevention. The Code is a preventive tool aimed to reduce the cancer burden by informing people how to avoid or reduce carcinogenic exposures, adopt behaviours to reduce the cancer risk, or t…

Cancer Researchmedicine.medical_specialtyQuality Assurance Health CareEpidemiologyUterine Cervical NeoplasmsCancer preventionCauses of cancerCancer screeningBreast cancerRisk FactorsEnvironmental healthCancer screeningmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unionPreventive healthcaremedia_commonCervical cancerCancer risk factorsCancer preventionbusiness.industryCancermedicine.diseaseEuropeOncology1117 Public Health And Health ServicesWorking Groups of Scientific ExpertsPractice Guidelines as TopicFemalebusiness1112 Oncology And Carcinogenesis
researchProduct

Human papillomavirus antibody responses among patients with incident cervical carcinoma

1997

The human papillomavirus (HPV) is recognized as a major cause of cervical cancer precursor lesions. HPV serology is a key method in the continuing elucidation of the importance of HPV exposure for cancer development and in predicting HPV-associated diseases. To extend previous HPV serological studies on cervical cancer, serum samples from a consecutive series of 216 women with incident untreated cervical carcinoma and 243 age- and sex-matched healthy blood donors were evaluated for the presence of antibodies against HPV capsids, a marker of past or present HPV exposure, as well as against several cervical cancer-associated defined HPV epitopes. Among the capsid antibody responses, HPV type …

AdultMolecular Sequence DataUterine Cervical NeoplasmsAntibodies ViralKlinikai orvostudományokEpitopeSerologyEpitopesCapsidRisk FactorsVirologyCarcinomamedicineHumansAmino Acid SequenceRisk factorAntigens ViralPapillomaviridaeAgedAged 80 and overCervical cancerbiologybusiness.industryPapillomavirus Infectionsvirus diseasesOrvostudományokMiddle Agedmedicine.diseaseVirologyfemale genital diseases and pregnancy complicationsTumor Virus InfectionsInfectious DiseasesCase-Control StudiesImmunologybiology.proteinFemaleHuman Papillomavirus AntibodyViral diseaseAntibodybusiness
researchProduct

Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA.

2004

In this article, we demonstrate that interaction of human papillomavirus-like particles (HPV-VLPs) with the putative glucosaminoglycan binding receptor is strictly dependent on conformational integrity. Such conformations are present on VLPs and capsomeres but not on monomers of the major capsid protein, L1, confirming reports that capsomeres can induce virus-neutralizing antibodies. Furthermore, we show the suitability of this specific interaction for development of VLP-based enzyme-linked immunosorbent assays (ELISAs), using heparin for indirect coupling of VLPs to microtiter plates, which may add an intrinsic quality control. This avoids presentation of linear, often highly cross-reactiv…

Protein DenaturationProtein ConformationvirusesEnzyme-Linked Immunosorbent AssayPlasma protein bindingCross ReactionsAntibodies ViralEpitopeEpitopesProtein structureVirus-like particleNeutralization TestsVirologyCentrifugation Density GradientHumansPapillomaviridaeGlycosaminoglycansbiologyHeparinCapsomerevirus diseasesOncogene Proteins ViralVirologyInfectious DiseasesProteoglycanCapsidbiology.proteinReceptors VirusCapsid ProteinsHeparan Sulfate ProteoglycansConformational epitopeProtein BindingJournal of medical virology
researchProduct

A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children.

1999

The importance and natural history of HPV infections in childhood is incompletely understood. We performed a survey for presence of serum antibodies to HPV capsids among 1031 children aged 0 to 13 years, resident in Stockholm, Sweden. The HPV seroprevalence among these children was 3.0% for HPV16, 0.6% for HPV18 and 2.7% for HPV33. By comparison, among simultaneously analyzed positive control panels comprising women with CIN or healthy women with type-specific cervical HPV DNA, seroprevalence of HPV 16, 18 and 33 was 69%, 58% and 63% respectively. The results suggest that HPV infection in childhood is not common.

Cancer Researchmedicine.medical_specialtyAdolescentvirusesAntibodies ViralSerologyCapsidInternal medicineEpidemiologymedicineSeroprevalenceHumansChildPapillomaviridaeSwedenbusiness.industryPublic healthPapillomavirus InfectionsHPV infectionInfant Newbornvirus diseasesInfantmedicine.diseasefemale genital diseases and pregnancy complicationsNatural historyTumor Virus InfectionsOncologyEl NiñoChild PreschoolImmunologyFemaleViral diseasebusinessInternational journal of cancer
researchProduct